Anixa Biosciences (ANIX) Q1 2026 earnings summary

Executive summary

• Focused on developing cancer vaccines and CAR-T therapies, with ongoing clinical trials in ovarian and breast cancer and preclinical work in additional cancer types.

• No revenue generated from therapeutics or vaccine programs to date; revenue derived from technology licensing and patent settlements.

• Sufficient cash, cash equivalents, and short-term investments to fund operations for at least the next 12 months.

Financial highlights

• Net loss for the quarter ended January 31, 2026 was $2.6 million, compared to $3.2 million for the same quarter last year.

• Research and development expenses decreased to $1.1 million from $1.6 million year-over-year, mainly due to lower costs in the breast cancer vaccine and CAR-T programs.

• General and administrative expenses decreased to $1.6 million from $1.8 million year-over-year, primarily due to lower stock-based compensation and patent costs.

• Interest income was $131,000, down from $173,000 year-over-year due to lower investment balances and rates.

• Cash, cash equivalents, and short-term investments totaled $14.2 million at quarter-end, down $972,000 from October 31, 2025.

Outlook and guidance

• No near-term revenue expected from therapeutics or vaccine programs; focus remains on advancing clinical trials and research collaborations.

• Management expects current liquidity to support operations for significantly longer than 12 months.